Jan 9 (Reuters) - AMAG Pharmaceuticals Inc:
* Sees Q4 revenue $16.5- $17.5 million, including between $14.5 -$15.5 million
in net product revenues for ferahemeinjection for intravenous (IV) use
* Says estimates that it ended 2010 with between $292 and $295 million in cash,
cash equivalents and investments
* Says sees between $55 and $60 million of feraheme net product revenues during
2011
* Sees incurring between $62 and $68 million in research and development
expenses, including $42 to $48 million in external costs related to clinical
trials,
((New York Equities Desk; tel: +1 646 223 6000))
(For more news about AMAG Pharmaceuticals Inc click here:) COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Sees Q4 revenue $16.5- $17.5 million, including between $14.5 -$15.5 million
in net product revenues for ferahemeinjection for intravenous (IV) use
* Says estimates that it ended 2010 with between $292 and $295 million in cash,
cash equivalents and investments
* Says sees between $55 and $60 million of feraheme net product revenues during
2011
* Sees incurring between $62 and $68 million in research and development
expenses, including $42 to $48 million in external costs related to clinical
trials,
((New York Equities Desk; tel: +1 646 223 6000))
(For more news about AMAG Pharmaceuticals Inc click here:) COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.